In the decades since its discovery, researchers have worked to find ways to ever so slightly alter erythromycin, to differentiate the antibiotics being produced and discourage bacteria from becoming accustomed, and therefore resistant, to them, Andrew Myers, PhD, lead author of the paper, told Genetic Engineering & Biotechnology News.
The method described in his new paper, however, would use combinations or substances derived from combinations of eight man-made molecules that would act similarly to antibiotics, but would require much less work to differentiate, offering more options for safe drugs that wouldn’t inspire resistance.
The paper outlines 350 compounds, two of which in initial tests proved effective against bacteria known to be resistant to last resort antibiotics, Dr. Myers told GenEn.
More articles on antibiotics:
FDA issues safety warning on side effects of popular antibiotics
Researchers look to mushroom isolates to develop antibiotics
FDA issues new reporting requirements for sales of antibiotics given to food-producing animals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
